JOSD2 inhibits nuclear localisation by reducing the lysine 433 acetylation of PKM2 in acute myeloid leukaemia (AML), thereby decreasing downstream gene expression and ultimately slowing AML progression.243. The gene discussed is PKM; the disease is acute myeloid leukemia.